Abionyx Pharma
ABNX
Company Profile
- Business description- Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy. 
- Contact- 33-43 Avenue Georges Pompidou-Bat D2 
 Balma31130
 FRA- T: +33 562249706 
- Sector- Healthcare - Stock type- Defensive 
- Industry- Biotechnology - Fiscal Year End- 31 December 2025 - Employees- 51 
Stocks News & Analysis
stocks
Microsoft earnings: Strong, including Azure, but overall guidance is in line
We think Microsoft stock is moderately undervalued.
stocks
After earnings, is Tesla stock a buy, a sell, or fairly valued?
Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.
Morningstar Investment Ideas
Markets
| Index | Last price | Change | % Change | 
|---|---|---|---|
| All Ordinaries | 9,178.00 | 28.70 | -0.31% | 
| CAC 40 | 8,121.07 | 79.81 | -0.97% | 
| DAX 40 | 23,958.30 | 160.59 | -0.67% | 
| Dow JONES (US) | 47,562.87 | 40.75 | 0.09% | 
| FTSE 100 | 9,717.25 | 42.81 | -0.44% | 
| HKSE | 25,906.65 | 376.04 | -1.43% | 
| NASDAQ | 23,724.96 | 143.81 | 0.61% | 
| Nikkei 225 | 52,411.34 | 1,085.73 | 2.12% | 
| NZX 50 Index | 13,548.32 | 89.03 | 0.66% | 
| S&P 500 | 6,840.20 | 17.86 | 0.26% | 
| S&P/ASX 200 | 8,881.90 | 31.30 | -0.35% | 
| SSE Composite Index | 3,954.79 | 32.11 | -0.81% |